NCT05488132招募中1 期
Application of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Xuzhou Medical University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity（DLT）
研究概览
简要总结
To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
详细描述
Sialic acid-binding immunoglobulin-like lectins (Siglec) are a class of classical immunoglobulin-like lectins. Studies have shown that Siglec-6 is commonly expressed in AML but not detected on normal hematopoietic stem and progenitor cells (HSC/P). In vitro experiments revealed that anti-Siglec-6 CAR-T cell treatment did not affect the viability or lineage differentiation in colony-forming assays. These data suggest that anti-SigLlec-6 is an ideal target with great potential for treating acute myeloid leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;
- •At the age of 18-70 years old;
- •Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);
- •The patient has recovered from the toxicity of previous treatment;
- •ECOG score ≤ 2 and expected survival period is not less than 3 months;
- •Adequate organ function defined as:AST ≤3×ULN; ALT ≤3×ULN; Total bilirubin ≤1.5×ULN; Serum creatinine ≤1.5×ULN, or CCR≥60 mL/min; Hemoglobin ≥60g/L ; Indoor oxygen saturation ≥92%; LVEF≥45%;
- •Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test;
- •From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception.
排除标准
- •Diagnosis of acute promyelocytic leukemia;
- •History or presence of a CNS disorder;
- •HBsAg is positive; HCV 、HIV or Syphilis antibody are positive, CMV DNA in peripheral blood is more than≥500 copies /mL;
- •History of severe hypersensitivity reaction;
- •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment;
- •History of organ transplant surgery;
- •Required systemic application of immunosuppressive or other drugs;
- •Auto-SCT within the 3 months before enrollment;
- •Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES));
- •Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ;
- •Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management;
- •Live vaccine received within the ≤ 4 weeks before enrollment;
- •Persons with serious mental illness;
- •History of major surgical operations four weeks before enrollment;
- •History of alcoholism or substance abuse;
- •Was identified by the investigators as unsuitable to participate in the study.
研究组 & 干预措施
anti-siglec-6 CAR-T cell therapy
Experimental
anti-siglec-6 CAR-T cell therapy
干预措施: anti-siglec-6 CAR-T cell therapy (Drug)
结局指标
主要结局
Dose-limiting toxicity（DLT）
时间窗: Baseline up to 28 days after T cell infusion
Adverse events assessed according to NCI-CTCAE v5.0 criteria
次要结局
- MRD negative overall response rate (MRD- ORR)(3 months)
- Overall response rate (ORR)(Month 6, 12, 18 and 24)
- Event-free survival (EFS)(Month 6, 12, 18 and 24)
- Overall survival (OS)(Time Frame: Month 6, 12, 18 and 24)
研究者
Kai Lin Xu，MD
President
Xuzhou Medical University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseNCT06125652Xuzhou Medical University20
招募中
不适用
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesMultiple MyelomaLymphomaAcute Lymphoblastic LeukemiaNCT05618041Hebei Senlang Biotechnology Inc., Ltd.50
招募中
早期 1 期
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesNon-Hodgkin's LymphomaAcute Lymphoblastic LeukemiaNCT04532203Zhejiang University72
Unknown
不适用
TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaCARAcute Myeloid LeukemiaNCT04692948PersonGen BioTherapeutics (Suzhou) Co., Ltd.5
进行中（未招募）
早期 1 期
Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid TumorsSafety and Efficacy of Cellular Drugs, Objective Response Rate of Subjects, EtcNCT06572956The Second Hospital of Shandong University10